LONDON, Oct. 26, 2015 /PRNewswire/ --
About Multiple Sclerosis
Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems. Multiple sclerosis can be broadly classified into four types: RRMS, SPMS, PPMS, and PRMS.
Technavio's analysts forecast the multiple sclerosis market in the US to grow at a CAGR of 3.8% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the multiple sclerosis market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of multiple sclerosis.
On the basis of route of administration of the drugs, the market is grouped into the following categories:
- Oral
- Parenteral
On the basis of type of molecule of the drugs, the market is grouped into the following categories:
- Small Molecules
- Biologics
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors and competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.
Technavio's report, the multiple sclerosis market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the multiple sclerosis market in US market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
- Bayer AG
- Biogen
- Merck Serono
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors
- AB Science
- Abbvie
- Acorda Therapeutics
- Active Biotech
- Artielle
- Astellas
- AstraZeneca
- Canbex
- F. Hoffmann-La Roche
- GeNeuro
- GlaxoSmithKline
- Glenmark
- InnoBioscience Pharmaceuticals
- Ipsen
- Mapi-Pharma
- medDay Pharmaceuticals
- MediciNova
- Mitsubishi Tanabe
- Opexa Therapeutics
- Osmotica
- Pfizer
- Receptos
- RedHill Biopharma
- Sanofi
- Trophos
- XenoPort
Market Driver
- Unmet Medical Needs.
- For a full, detailed list, view our report.
Market Challenge
- Unknown Disease Etiology.
- For a full, detailed list, view our report.
Market Trend
- Introduction of Disease-modifying Drugs.
- For a full, detailed list, view our report.
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Download the full report: https://www.reportbuyer.com/product/3095494/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article